It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The change may not be palatable to everyone, but asthmatics should take comfort in the fact that their medicine is no longer destroying the ozone layer.
cleantechnica.com...
The fluorescent devices produce a more intense light and can aggravate a range of existing problems, especially in those with light-sensitive conditions. Eco-bulbs are due to become compulsory in British homes within four years. But campaigners want the Government to allow an opt-out so people with health problems can still use old-style incandescent bulbs.
There have been growing concerns that low-energy light can trigger migraines, as well as dizziness, loss of focus and discomfort among those with epilepsy. There have also been complaints from sufferers of lupus - an auto-immune disease causing many symptoms including pain.
www.thisislondon.co.uk...
EU to ban traditional light bulbs, but at what cost to health and the environment?
Natural News reports that “according to health advocates including the Skin Care Campaign, Spectrum and even the British Association of Dermatologists, fluorescent light bulbs are known to worsen skin rashes in people with a variety of diseases and conditions including dermatitis, eczema, lupus, photosensitivity, porphyria and Xeroderma Pigmentosum.”
“The groups warned that a complete ban on incandescent lighting for people with such conditions would violate the Disability Discrimination Act, and that employers should also be allowed to purchase incandescent lights if their employees have a need for them.”
Normal lightbulbs on prescription perhaps? I wonder what the ’street’ value would be
stewartcowan.wordpress.com...
Environmental scientists and waste industry officials are warning that a massive shift to compact fluorescent light bulbs will lead to far more mercury contamination than has been widely supposed.
With the increasing popularity of granite countertops, a wide variety of granites are now available from all over the world. A surprising number of these, like the one used in Sugarman's kitchen, contain uranium and give off radiation at several times above the background level.
According to the EPA, a normal person is exposed to a "background level" of 360 millirem of radiation per year from both natural and industrial sources. The Nuclear Regulatory Commission says that people living near nuclear reactors should not be exposed to more than100 millirem above background level in a given year.
Furthermore, CFLs contain mercury and other harmful substances that can be dangerous if the bulb is broken. It is also illegal in many countries, including Germany, to dispose of them in household trash. At present, there is no system for the disposal of such light bulbs in Germany, forcing consumers to take expired bulbs to electronic recycling centers themselves.
www.spiegel.de...
Originally posted by melatonin
Problem is, though, double-blind studies have demonstrated that HFA-based inhalers are as effective as CFC-based inhalers. In other words, when people didn't know they were using a different medicine source, it made no difference to the effect on symptoms.
People are so resistant to change, I guess it would be hard to separate a real problem from the psychological. And I'm seeing lots of other more psych (and I don't mean psychopathology, lol) issues that would suggest that possibility in this thread and t'other.
Originally posted by AshleyD
Originally posted by melatonin
Problem is, though, double-blind studies have demonstrated that HFA-based inhalers are as effective as CFC-based inhalers. In other words, when people didn't know they were using a different medicine source, it made no difference to the effect on symptoms.
That's an interesting study. Thank you very much for adding that in the thread.
Proventil HFA Provides Bronchodilation Comparable to Ventolin Over 12 Weeks of Regular Use in Asthmatics
Eugene R. Bleecker MD, FCCP1; David G. Tinkelman MD2; Joe Ramsdell MD3; Bruce P. Ekholm MSc4; Nancy M. Klinger BSc4; Gene L. Colice MD, FCCP4; and Herbert B. Slade MD4
Objective: To compare the bronchodilator effectiveness of albuterol reformulated in the chlorofluorocarbon-free propellant hydrofluoroalkane (HFA)134a (Proventil HFA) to that of Ventolin and HFA placebo over 12 weeks of regular dosing.
Design: Randomized, double-blind, double-dummy, parallel group, placebo-controlled, multicenter trial of asthmatics requiring inhaled β-adrenergic bronchodilators for symptom control.
Interventions: Treatment qid with Proventil HFA, Ventolin, or HFA-134a placebo for 12 weeks.
Measurements: At weeks 0, 4, 8, and 12, spirometry was performed predose and serially over 6 h after dosing with study drug. Bronchodilator efficacy variables, based on FEV1 response to study drug, were proportion of responders, time to onset of effect, peak percent change, time to peak effect, duration of effect, and area under the curve (AUC).
Results: Demographic and baseline characteristics were similar for patients randomized to Proventil HFA (193), Ventolin (186), and HFA-134a placebo (186). No significant differences were found between the Proventil HFA and Ventolin treatment groups for any FEV1 efficacy variable, either predose or during 6 h of serial spirometry, at weeks 0, 4, 8, and 12. For all efficacy variables, except time to onset of effect, the Proventil HFA and Ventolin results were significantly greater than placebo. Time to onset of effect for the HFA-134a placebo group is misleading; only 13 patients (7%) were found to be responders in the intent-to-treat database. These efficacy results were found to be consistent across subgroup analyses of inhaled and nasal corticosteroid use, age (18 to 35 and 36 to 66 years), sex, race, weight (100 kg), and baseline FEVl (55% and >55% predicted). The peak FEV1 effect, duration of FEV1 effect, and AUC for FEV1 were all significantly smaller at weeks 4, 8, and 12 than week 0 for both the Proventil HFA and Ventolin treatment groups.
Conclusions: Proventil HFA provided bronchodilation comparable to Ventolin and superior effects to HFA-134a placebo over 12 weeks of regular dosing. There was a diminution in bronchodilator response to both Proventil HFA and Ventolin after 4 weeks of use.
Key Words: albuterol • asthma • HFA-134a propellant
Submitted on March 18, 1997
Accepted on July 28, 1000
This time was different though. After picking up my prescription from the pharmacy for this new inhaler, as of the first puff I turned to my husband and asked what in the world is this? He then told me about the changes for the environment and that they took the 'push' out of the new inhalers. So I picked up on the change instantly without knowing there had been a change.
Just a couple of differences I noticed immediately before I even knew there had been a change:
1). The force in which the medicine is expelled from the inhaler is very, very weak compared to the old style. Instead of it being sprayed into constricted lungs, you have to forcefully suck in the medicine to ensure it gets inhaled.
2). I had to take two puffs to feel the relief that one puff of my old inhaler provided.
3). The size of the inhaler which was about half of what I'm normally subscribed.
Originally posted by ZindoDoone
Meletonin,
Its not just the propelant though. For those of use who pay for our own perscriptions the price went up 40%. You take Albuterol for instance. It's one of the few I can inhale with no problems. I used to pay 76.00 for one month. Now. its 107.00 per month. No difference other then the change from CFC's!
Zindo
Originally posted by AshleyD
our disappointment and frustration due to the product change that has resulted in a more expensive and less effective product. The reason? A little 1/5 of a second squirt from the older type is allegedly destroying the O-zone layer.